DIAGNOS Will Utilize its Artificial Intelligence Medical Platform FLAIRE in Response to the “US White House - Call to Actio...
March 25 2020 - 07:45AM
DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK)
(OTCQB: DGNOF), a leader in early detection of critical health
issues through the use of Artificial Intelligence (AI), announces
that it is participating in the “Call to Action” initiative
implemented by the White House Office of Science and Technology
Policy. DIAGNOS has accessed a significant dataset with the
objective of analysing these medical documents with its AI Medical
Platform, called FLAIRE, in order to identify key factors that
could assist in the battle against the Coronavirus.
In response to the COVID-19 pandemic, the White
House and a coalition of leading research groups have prepared the
COVID-19 Open Research Dataset (CORD-19). CORD-19 is a resource of
over 44,000 scholarly articles, including over 29,000 with full
text, about COVID-19, SARS-CoV-2, and related coronaviruses. This
dataset is provided to the global research community to apply
recent advances in natural language processing and other AI
techniques to generate new insights in support of the ongoing fight
against this infectious disease. There is a growing urgency for
these approaches because of the rapid acceleration in new
coronavirus literature, making it difficult for the medical
research community to keep up.
Call to Action (from the White
House)
The White House is issuing a call to action to
the world's artificial intelligence experts to develop text and
data mining tools that can help the medical community develop
answers to high priority scientific questions. The CORD-19 dataset
represents the most extensive machine-readable coronavirus
literature collection available for data mining to date. This
allows the worldwide AI research community the opportunity to apply
text and data mining approaches to find answers to questions
within, and connect insights across, this content in support of the
ongoing COVID-19 response efforts worldwide.
Mr. André Larente, CEO of
Diagnos stated: “Diagnos AI platform has been
built to address the complexity of multiple sources of data that
includes text mining, data mining and medical imaging. The
proprietary technology has been developed over a number of years in
order to identify medical challenges, for example cardio vascular
issues have resulted in new tests to address hypertensive patient
complications and to predict a potential stroke. The intention of
FLAIRE in response to the White House Call to Action is to assist
in resolving some of the issues caused by the virus by analyzing
the dataset made available by the US authorities.’’
The Standing Committee on Emerging Infectious
Disease and 21st Century Health Threats of the US and the WHO
identified 10 scientific questions that are vital to address this
international crisis. These questions include studying the
transmission and incubation of the virus, risk factors for getting
the COVID-19, the origin of the virus, and the proper medical
practice for treating this disease.
Mr. Francis Bellido, PhD in
Medical Microbiology and board member at Diagnos
added: “One outcome that is particularly ”remarkable” in the
COVID-19 crisis is that the majority of the deceased victims had
one or several pre-condition(s) before the infection struck such as
hypertension, diabetes, obesity or other Cardio Vascular issues,
which are the “sweet spots” for the Diagnos diagnostic assisted
platform. We believe that this virus could further alter the
cartography of the retina in such patients, and if confirmed,
creating the possibility of an additional facet to our existing
detection tool for our existing patients.’’
Dr. Hadi Chakor, Chief
Medical Officer at Diagnos added: ‘’One of the treatments
for COVID-19 is the use of chloroquine or hydroxychloroquine. The
recommendations of the American Academy of Ophthalmology on the
screening of chloroquine (CQ) and hydroxychloroquine (HCQ) are very
clear after taking high doses and for a long period of use, a
rigorous follow-up with patients is required. These conditions
represent the most severe risks of developing morphological
alterations in the retina after treatment with chloroquine. Also,
previous studies demonstrate clearly that chloroquine disrupts
lysosomal function in retinal neurons and RPE. Modern screening
should be based on primary AI-based automatic screening tests to
assess the fundus plus optical spectral coherence tomography (SD
OCT) exams. These investigations should look beyond the central
macula to provide objective screening and to detect subtle changes
on the retinal membrane.’’
The Corporation is also announcing a correction
to its press release dated March 9th, 2020: The number of common
shares that Mr. Tristram Coffin would hold assuming the exercise of
stock warrants should read 11,047,561
instead of 10,624,560. About DIAGNOS
DIAGNOS is a publicly-traded Canadian
corporation with a mission of early detection of critical health
issues through the use of its Artificial Intelligence (“AI”)
platform FLAIRE. Diagnos can build application rapidly using the
FLAIRE platform such as CARA (Computer Assisted Retina Analysis).
CARA is an application that integrates with existing equipment
(hardware and software) and processes at the point of care. CARA’s
Artificial Intelligence image enhancement algorithms make standard
retinal images sharper, clearer and easier to read. CARA is a
cost-effective tool for screening large numbers of patients in
real-time and has been cleared for commercialization by several
regulatory authorities such as Health Canada, the U.S. Food and
Drug Administration, European Union and other countries.
Additional information is available at
www.diagnos.com and www.sedar.com.
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publically update or revise any forward-looking information,
whether as a result of new information, future events or otherwise.
The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release. For further information,
please contact:
Mr. André Larente, President |
DIAGNOS Inc. |
Tel: 450-678-8882 ext. 224 |
alarente@diagnos.ca |
Diagnos (TSXV:ADK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Mar 2023 to Mar 2024